Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Promising combo tackles relapsed lymphoma in small trial

NCT ID NCT02433795

Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tested a combination of two drugs, bendamustine and rituximab, in 27 people with relapsed or progressive marginal zone B-cell lymphoma. The goal was to see how well the treatment shrank or controlled the cancer. Participants had already tried at least one prior therapy. The study is complete, and results may help guide future treatment for this type of lymphoma.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bendamustine plus rituximab
What this could lead to
If successful, this combination could offer a treatment option for people with relapsed marginal zone lymphoma, helping to shrink or control the cancer.
What could go wrong
This is a small, phase 2 study with only 27 participants, so results may not apply to everyone. The treatment also has side effects like low blood counts and infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

27 people

The number who actually took part.

Start date

May 2015

Finished

Oct 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Histologically confirmed CD20-positive nodal or extranodal MZBCL 2. MZBCL patients who relapsed or progressed: * At least one and a maximum of four prior lines of chemotherapy * During or after the last chemotherapy or radiotherapy or * Without progression within 6 months of the last dose of rituximab-based regimen 3. Patients age ≥ 18 years 4. ECOG PS 0-2 5. At least one bidimensionally measurable disease 6. Adequate hematologic, renal, and hepatic functions 7. Women of child-bearing potential should use two appropriate methods of contraception during the study 8. Written informed consent Exclusion Criteria: 1. Not all of the above inclusion criteria are met. 2. Prior chemotherapy within 4 weeks or radiotherapy within 6 weeks 3. Corticosteroids during last 28 days except chronic administration of prednisolone at a dose of \< 20mg/day for indications other than lymphomas 4. Evidence of CNS involvement by lymphomas 5. Active HBV/HCV infections, known HIV infection 6. Prior diagnosis of cancers within 5 years, except cervical intraepithelial neoplasia type 1, localized non-melanoma skin cancer, or small differentiated thyroid cancer 7. Serious concurrent disease: 8. Patients who are pregnant or lactating

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Marginal zone B cell lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Lymphoma, B-Cell, Marginal Zone marginal zone lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Marginal zone B cell lymphoma

Contacts and locations

Locations

  • Chonbuk National University Hospital

    Jeonju, Jeollabuk-do, 54907, South Korea

  • Chungnam National University

    Daejeon, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Gyeongsang National University Hospital

    Jinju, South Korea

  • Hallym University Medical Center

    Anyang-si, South Korea

  • Inje Universit

    Seoul, South Korea

  • Korea Cancer Center Hospital

    Seoul, South Korea

  • Seoul National University Boramae Hospital

    Seoul, South Korea

  • Seoul National University Bundang Hospital

    Seongnam, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • The Catholic University of Korea

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.